enGene Therapeutics (ENGN) Cash from Operations (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Cash from Operations data on file, last reported at -$18.9 million in Q3 2026.

• For the quarter ending Q3 2026, Cash from Operations rose 26.09% year-over-year to -$18.9 million; the trailing twelve-month figure through Jul 2026 stood at -$103.3 million (down 10.08% YoY), and the FY2025 full-year result was -$99.2 million, down 105.54% from the prior year.
• Cash from Operations was -$18.9 million for Q3 2026 at enGene Therapeutics, up from -$30.5 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$4.4 million in Q2 2023 to a low of -$30.5 million in Q2 2026.
• A 4-year average of -$16.7 million and a median of -$18.9 million in 2026 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 256.97% in 2025 and gained 26.09% in 2026, its largest moves.
• enGene Therapeutics' Cash from Operations stood at -$6.8 million in 2023, then plunged by 188.78% to -$19.6 million in 2024, then slipped by 27.57% to -$25.0 million in 2025, then grew by 24.1% to -$18.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$18.9 million in Q3 2026, -$30.5 million in Q2 2026, and -$28.9 million in Q1 2026.